Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S360100
Reexamination Certificate
active
07981918
ABSTRACT:
The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.
REFERENCES:
patent: 2008/0207691 (2008-08-01), Aicher et al.
patent: 2008/0214621 (2008-09-01), Aicher et al.
patent: 2008/0275043 (2008-11-01), Aicher et al.
patent: 2009/0275613 (2009-01-01), Li et al.
patent: 2009/0069326 (2009-03-01), Allen et al.
patent: 2009/0088428 (2009-04-01), Saeed et al.
patent: 2009/0088430 (2009-04-01), Wallace et al.
patent: 2009/0099180 (2009-04-01), Mabry et al.
patent: 2009/0099182 (2009-04-01), Li et al.
patent: 2009/0111809 (2009-04-01), Bush
patent: 2009/0156571 (2009-06-01), Aicher et al.
patent: 2009/0239911 (2009-09-01), Wallace et al.
patent: 2009/0264650 (2009-10-01), Toshiro et al.
patent: 1864971 (2007-12-01), None
patent: WO 2004/056744 (2004-07-01), None
patent: WO 2005/108360 (2005-11-01), None
patent: WO 2005/108361 (2005-11-01), None
patent: WO 2006/040329 (2006-04-01), None
patent: WO 2006/049952 (2006-05-01), None
patent: WO 2006/053024 (2006-05-01), None
patent: WO 2006/068991 (2006-06-01), None
patent: WO 2006/068992 (2006-06-01), None
patent: WO 2006/104280 (2006-10-01), None
patent: WO 2007/084314 (2007-07-01), None
patent: WO 2007/012688 (2007-11-01), None
patent: WO 2007/124329 (2007-11-01), None
patent: WO 2007/124337 (2007-11-01), None
patent: WO 2007/127693 (2007-11-01), None
patent: WO 2007/127704 (2007-11-01), None
patent: WO 2007/127726 (2007-11-01), None
patent: WO 2007/127763 (2007-11-01), None
patent: WO 2007/127765 (2007-11-01), None
patent: WO 2007/127901 (2007-11-01), None
patent: WO 2008/157752 (2008-12-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta et al., abstract, Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
A. Maureen Rouhi, The Right Stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls, Chem. & Eng. News, 81(8), Feb. 24, 2003, 32-35.
Brittain, H.G. (Polymorphism in Pharmaceutical Solids—Drugs and the Pharmaceutical Sciences, V. 95; New York Marcel Dekker, Inc., 1999), p. 236.
Yeh et al.: Discovery of orally active butyrolactam 11 β-HSD1 inhibitors, Bioorganic & Medicinal Chemistry Letters, Nov. 1, 2006, 16(21), pp. 5555-5560.
Schuster, Daniela et al.: The Discovery of New 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors by Common Feature Pharmacophore Modeling and Virtual Screening, J. Medicinal Chemistry, 2006, 49, pp. 3454-3466.
Konno et al.: Electrolytic Partial Fluorination of Organic Compounds. 6. Highly Regioselective Eletrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles, Tetrahedron Letters, 1992, vol. 33, No. 46, pp. 7017-7020.
Aicher Thomas Daniel
Anzeveno Peter Biagio
Krasutsky Alexei Pavlovych
Li Renhua
Mabry Thomas Edward
Anderson Rebecca L
Eli Lilly and Company
Shterengarts Samantha L
Wood Dan L.
LandOfFree
Cyclohexylpyrazole-lactam derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclohexylpyrazole-lactam derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexylpyrazole-lactam derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2716061